Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine is a synthetic small molecule belonging to the class of naphthalenecarboxamides. It has a molecular formula of C23H24N4O and a molecular weight of approximately 372.5 g/mol[1][5][2]. The compound is listed as experimental and does not have an assigned therapeutic indication or approved use in humans[7]. Its mechanism of action and biological targets are not described in available public databases. There are no known clinical trials or regulatory approvals for this compound as a pharmaceutical agent[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine.